A Deep Analysis Of The Market Landscape And The Competitive Situation Of Major Manufacturers

A deep analysis of the market landscape and the competitive situation of major manufacturers
As a fundamental and indispensable instrument in the modern medical system, puncture needles exhibit a complex characteristic of significant specialization and market concentration globally and regionally. According to the latest authoritative industry statistics in 2025, the overall scale of the global puncture needle market has risen to 5.87 billion US dollars, and the scale of the Chinese market has exceeded 9.4 billion yuan, with a compound annual growth rate consistently maintaining at a high level of 12.3%. This strong growth trend is mainly driven by multiple factors such as the acceleration of the global aging process, the continuous surge in the demand for chronic disease management, and the continuous improvement of the penetration rate of minimally invasive surgeries in clinical treatment.
From the perspective of the global macro competitive landscape, the market leadership is currently still held by international top medical equipment giants. Among them, BD (Becton, Dickinson and Company) is the absolute leader in the industry, with a market share of 25.38% in the key market segment of disposable puncture biopsy needles globally, and its position is stable. The company's product line layout is extremely comprehensive, covering a full range of clinical solutions from fine needle puncture biopsy to vacuum-assisted biopsy, and it has significant brand and channel advantages in mature markets such as North America and Europe. Another giant, Medtronic, has occupied a crucial position in the percutaneous puncture needle market by virtue of its long-term accumulated deep technology and clinical resources in cardiovascular intervention and neurointervention fields, especially in high-end clinical application scenarios such as atrial septal puncture, where its product performance is particularly outstanding.
In contrast, the Chinese market is witnessing an accelerated process of domestic medical device substitution of imported products under the dual influence of policy guidance and market demand. Leading domestic enterprises such as Nanwei Medical and Kangdelai have continuously expanded their market share through continuous technological iteration and efficient large-scale production. Data shows that by 2025, the domesticization rate of key categories of puncture needles has successfully exceeded the 45% threshold, and this proportion is expected to continue to increase rapidly in the coming years. Specifically, Nanwei Medical has established a significant competitive advantage in the sub-segment of digestive endoscopy supporting puncture needles due to its profound technical accumulation; while Kangdelai has performed exceptionally well in the disposable anesthesia puncture needle market, demonstrating outstanding performance and widespread clinical recognition.
From the perspective of the product structure's subdivision, disposable puncture needles, due to their advantages in preventing cross-infection and enhancing operational convenience, have indisputably become the absolute mainstream of the market, occupying 84% of the overall market share. In this category, the fully automatic disposable puncture biopsy needle has the highest market share of 85.9%, which profoundly reflects the continuous pursuit of clinical terminals for operational convenience and patient safety. In terms of the distribution of application scenarios, the public hospital system, with its large scale of diagnosis and treatment and complex case handling capabilities, remains the main consumer terminal of puncture needles, occupying 80.72% of the market share.
In terms of the development trend of regional markets, the North American region, with its mature medical system and strong payment capacity, still holds the dominant position in the global market. However, the Asia-Pacific region, especially the Chinese market, is demonstrating a global-leading growth rate. China is not only the largest and most dynamic emerging market globally, but also the technological innovation and product iteration capabilities of its local enterprises are rapidly improving. A number of outstanding local enterprises such as Weigao Co., Ltd., Intem (Wuhan) Medical Technology, and Shanghai Kailitai Medical Technology are gradually establishing unique competitive advantages in their respective fields through focused strategies on specific clinical needs and in-depth competition in specialized segments.
Looking ahead, the focus of market competition will increasingly concentrate on core technological innovation capabilities and the efficiency of integrating the entire industrial chain. Multinational enterprises are strengthening their control over the upstream and downstream industrial chains and synergy through frequent mergers and acquisitions; meanwhile, local enterprises are fully leveraging the support of national industrial policies and their localized cost advantages to actively seek key breakthroughs in high-end and intelligent product areas. With the continuous advancement of medical policy reforms such as national bundled procurement, price competition in the market will become more intense. At that time, those enterprises that simultaneously possess strong production cost reduction capabilities and continuous core technology research and development advantages will have more extensive development space in the new round of industry reshuffling.